Genentech wins FDA nod for subcutaneous formulation of arthritis drug

Roche‘s (OTC:RHHBY) Genentech reported this week that the FDA approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients two years and older. The U.S. agency approved the intravenous formulation of Actemra for the same indication in 2011. Get the full story at our sister site, Drug Delivery Business News.   The post Genentech wins FDA nod for subcutaneous formulation of arthritis drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Orthopedics Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Source Type: news